EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of alternating denosumab and zoledronic acid for osteonecrosis of the femoral head in children

Myra Poon, Joel Vanderniet, Christie-Lee Wall, Suzie Taylor, Jessica Sandy, Andrew Biggin, Craig F Munns

Bone · 2027

DOI: 10.1016/j.bone.2026.118124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2027. Verfasst von Myra Poon und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales, 2145, Australia; Sydney Medical School, Faculty of Medicine and Heal…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Denosumab, Femur Head Necrosis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteonecrosis, or avascular necrosis, of the femoral head (ONFH) results from an avascular insult of traumatic or non-traumatic origin and can lead to significant morbidity, including pain, arthritis and the need for joint replacement at a young age. Non-surgical management of ONFH focuses on preservation of femoral head shape to reduce the need for arthroplasty or delay the age at which it is performed. Thirty patients diagnosed with ONFH on bone scan were prospectively studied to determine the safety of alternating denosumab and zoledronic acid over a 66-week treatment period. Patients underwent 6-weekly scheduled biochemical monitoring and assessment of bone mineral density at baseline and after twelve months. Mild hypercalcaemia (range 2.65-2.85 mmol/L) was noted in 5 patients (16%) during the treatment period. One of these patients was subsequently diagnosed with familial hypocalciuric hypercalcaemia. Asymptomatic hypocalcaemia (range 1.79-2.00 mmol/L) was detected on routine biochemical testing in a total of 15 patients (48%). All episodes responded to an increase in oral calcium supplementation. Bone mineral density (BMD) increased in all patients following treatment, with maximum total body height-adjusted Z-score +2.4 and lumbar spine +3.3. There were no episodes of medication-related osteonecrosis of the jaw, atypical femoral fracture or hypophosphataemia. Our study demonstrates that, with regular monitoring and management of serum calcium, alternating doses of denosumab and zoledronic acid can be administered safely for ONFH in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBone Density Conservation AgentsDenosumabFemur Head NecrosisZoledronic AcidAdolescentChildFemaleHumansMaleBone DensityDiphosphonatesImidazoles

Stichwörter der Autor:innen

Avascular necrosisDenosumabFemoral headOsteonecrosisPaediatric

Substanzen

Antibodies, Monoclonal, HumanizedBone Density Conservation AgentsDenosumabDiphosphonatesImidazolesZoledronic Acid

Autor:innen und Institutionen

  • The Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales, 2145, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, 2006, Australia. Electr…
  • Sydney Children's Hospital, High Street, Randwick, New South Wales, 2031, Australia; School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
  • The Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales, 2145, Australia.
  • Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, 2006, Australia; Department of Endocrinology, Queensland Children's Hospital, South Brisbane, Queensland, 4101, Australia…
  • Department of Endocrinology, Queensland Children's Hospital, South Brisbane, Queensland, 4101, Australia; Medical School, The University of Queensland, Herston, Queensland, 4006, Australia.

Zitieren

APA

Poon, M., Vanderniet, J., Wall, C. L., Taylor, S., Sandy, J., Biggin, A., & Munns, C. F. (2027). Safety of alternating denosumab and zoledronic acid for osteonecrosis of the femoral head in children. Bone. https://doi.org/10.1016/j.bone.2026.118124

Vancouver

Poon M, Vanderniet J, Wall CL, Taylor S, Sandy J, Biggin A, et al. Safety of alternating denosumab and zoledronic acid for osteonecrosis of the femoral head in children. Bone. 2027. doi:10.1016/j.bone.2026.118124

BibTeX
@article{Poon2027,
  author = {Poon, Myra and Vanderniet, Joel and Wall, Christie-Lee and Taylor, Suzie and Sandy, Jessica and Biggin, Andrew and Munns, Craig F},
  title = {Safety of alternating denosumab and zoledronic acid for osteonecrosis of the femoral head in children},
  journal = {Bone},
  year = {2027},
  doi = {10.1016/j.bone.2026.118124}
}
Kostenlos starten →